Onfi (clobazam) works by enhancing the activity of GABA, the brain’s primary calming chemical. It belongs to the benzodiazepine family but has a slightly different molecular structure that gives it a stronger anti-seizure effect relative to its sedative side effects. The FDA approved it specifically for seizures associated with Lennox-Gastaut syndrome, a severe form of childhood epilepsy.
How Onfi Calms Overactive Brain Signals
Your brain cells communicate through electrical and chemical signals. In epilepsy, some of these signals fire too rapidly or spread too widely, causing seizures. GABA is a neurotransmitter that acts like a brake on this electrical activity. When GABA attaches to its receptor (called the GABA-A receptor) on the surface of a brain cell, it opens a channel that lets chloride ions flow in. This influx of chloride makes the cell less likely to fire.
Onfi doesn’t replace GABA or activate the receptor on its own. Instead, it attaches to the GABA-A receptor at a separate spot and amplifies the effect GABA already has. Think of it as making the brake pedal more responsive: each time GABA presses the brake, the cell slows down more than it would without the drug present. This reduces the likelihood of the runaway electrical activity that triggers seizures.
What Makes Onfi Different From Other Benzodiazepines
Most benzodiazepines, like diazepam and clonazepam, share a core chemical structure called a 1,4-benzodiazepine. Onfi is a 1,5-benzodiazepine, meaning the nitrogen atoms in its ring sit in different positions. This seemingly small change has a practical consequence: animal studies show clobazam has a favorable anticonvulsant profile with minimal motor impairment compared to traditional 1,4-benzodiazepines like diazepam and clonazepam.
Onfi also shows a preference for certain subtypes of the GABA-A receptor. Both clobazam and its active breakdown product bind more strongly to receptors containing the alpha-2 subunit than to those with the alpha-1 or alpha-3 subunits. The alpha-1 subunit is heavily linked to sedation, so this selectivity helps explain why Onfi controls seizures with somewhat less drowsiness than older benzodiazepines.
The Active Metabolite That Extends Its Effects
Once you take Onfi, your liver breaks it down into a second compound called N-desmethylclobazam. This metabolite is active, meaning it also enhances GABA signaling in the brain. Estimates of its potency range from about one-fifth the strength of the parent drug to roughly equal, depending on the measure used. What makes it significant is how long it sticks around: clobazam itself has a half-life of 36 to 42 hours, but N-desmethylclobazam has a half-life of 71 to 82 hours. That means the metabolite takes roughly three to three and a half days to drop to half its level in the blood.
This long-lasting metabolite creates a sustained anti-seizure effect between doses. It also means the drug builds up in your system over several days before reaching a steady state, which is why dosing starts low and increases gradually.
How the Body Processes Onfi
Two liver enzymes do most of the work converting clobazam into its active metabolite: CYP3A4 and CYP2C19. This matters because roughly 2 to 5% of the population (and higher percentages in certain ethnic groups) are “poor metabolizers” of CYP2C19. In these people, the active metabolite clears much more slowly, leading to higher levels in the blood and a greater risk of side effects like excessive sedation.
For known CYP2C19 poor metabolizers, the FDA-approved labeling recommends starting at 5 mg per day and titrating more slowly, generally to half the usual target dose. If needed, further increases up to the maximum dose (20 mg/day or 40 mg/day depending on body weight) can begin around day 21, guided by how the patient responds.
Onfi is available as both a tablet and an oral suspension. The two forms are bioequivalent, meaning they deliver the same amount of drug into the bloodstream.
How Effective Onfi Is at Reducing Seizures
The pivotal trial that led to FDA approval studied patients with Lennox-Gastaut syndrome and measured the change in weekly “drop seizures,” the sudden falls that are a hallmark of this condition. Patients on placebo saw a 12% reduction. Those on clobazam saw dose-dependent improvements: a 41% reduction at the low dose (up to 10 mg/day), 49% at the medium dose (up to 20 mg/day), and 68% at the high dose (up to 40 mg/day). All three clobazam groups showed statistically significant improvements over placebo.
These numbers represent averages across the study population. Individual responses vary, but the results are striking for a condition that is notoriously difficult to treat. Many patients with Lennox-Gastaut syndrome are already on multiple anti-seizure medications, and Onfi provided meaningful additional benefit on top of those existing regimens.
Why Stopping Onfi Requires a Gradual Taper
Because Onfi is a benzodiazepine, your brain adapts to its presence over time. Stopping abruptly can trigger withdrawal symptoms, including rebound seizures that may be worse than the original pattern. The general approach for tapering any benzodiazepine is to reduce the dose by about one-tenth at each step, with at least one week between reductions. Larger initial doses allow for slightly bigger reductions at the start, with smaller steps as the dose gets lower.
The long half-life of Onfi’s active metabolite means its levels decline slowly even after a dose reduction. This provides some natural cushion during a taper, but it also means withdrawal effects can appear days after a change rather than immediately. Any tapering plan should be guided by how you’re responding at each step rather than following a rigid calendar.